CNR1 and scleroderma: With respect to the non-CB1/non-CB2 cannabinoid-activated pathways, it should also be noted that administration of WIN55,212-2 (1–10 μM) reduced expression of TGF-β and CTGF, as well as deposition of the extracellular matrix, and suppressed transdifferentiation of scleroderma fibroblasts into myofibroblasts and abrogated resistance to apoptosis.